At Aquila, we can help you understand the role of your drug candidate on oligodendrocyte behaviour and myelination.
We offer screening of primary oligodendrocyte progenitor (NG2+) cells. A promising therapeutic strategy for Multiple Sclerosis is to promote Oligodendrocyte Precursor Cells (OPC) differentiation and maturation into oligodendrocytes (MBP+ cells), repairing myelin degeneration. Understanding the effect of your drug candidate on OPCs to enhance remyelination early in discovery is key to bringing new treatments to clinic.
Understanding the remyelination efficiency of your drug candidate in three dimensions offers a translational link between in vitro cell culture and in vivo investigations, a step up in complexity from our screening assay, and your best route to clinic.
Using our organotypic brain slice assays, we can help you understand the functional effects of your compounds. We can determine the degree of axon (re)myelination by oligodendrocytes, during development or following demyelination, mimicking an MS lesion. We can tailor the assay readouts to your requirements e.g. fluorescent imaging and gene expression analysis by qPCR. To find out more click here.
To discuss how we can support your CNS research program, please get in touch.